Targeting the treatment of drug abuse with molecular imaging.

Targeting the treatment of drug abuse with molecular imaging. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Targeting the treatment of drug abuse with molecular imaging. Abstract Text:

Wynne K Schiffer,Courtney N B Liebling,Vinal Patel,Stephen L Dewey,Wynne K Schiffer,Courtney N B Liebling,Vinal Patel,Stephen L Dewey,Wynne K Schiffer,Courtney N B Liebling,Vinal Patel,Stephen L Dewey,

Although imaging studies in and of themselves have significant contributions to the study of human behavior, imaging in drug abuse has a much broader agenda. Drugs of abuse bind to molecules in specific parts of the brain in order to produce their effects. Positron emission tomography (PET) provides a unique opportunity to track this process, capturing the kinetics with which an abused compound is transported to its site of action. The specific examples discussed here were chosen to illustrate how PET can be used to map the regional distribution and kinetics of compounds that may or may not have abuse liability. We also discussed some morphological and functional changes associated with drug abuse and different stages of recovery following abstinence. PET measurements of functional changes in the brain have also led to the development of several treatment strategies, one of which is discussed in detail here. Information such as this becomes more than a matter of academic interest. Such knowledge can provide the bases for anticipating which compounds may be abused and which may not. It can also be used to identify biological markers or changes in brain function that are associated with progression from drug use to drug abuse and also to stage the recovery process. This new knowledge can guide legislative initiatives on the optimal duration of mandatory treatment stays, promoting long-lasting abstinence and greatly reducing the societal burden of drug abuse. Imaging can also give some insights into potential pharmacotherapeutic targets to manage the reinforcing effects of addictive compounds, as well as into protective strategies to minimize their toxic consequences.

Targeting the treatment of drug abuse with molecular imaging. Publishing Authors By Initials

WK Schiffer,CN Liebling,V Patel,SL Dewey,WK Schiffer,CN Liebling,V Patel,SL Dewey,WK Schiffer,CN Liebling,V Patel,SL Dewey,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Targeting the treatment of drug abuse with molecular imaging. Journal Published:

PUBLICATION TYPE: Research Support, U.S. Gov't,

Journal: Nuclear medicine and biology

VOLUME: 34

Page Numbers: 833-47

Journal Abbreviation: Nucl. Med. Biol.

ISSN: 0969-8051

DAY: 9

MONTH: 08

YEAR: 2007

Targeting the treatment of drug abuse with molecular imaging. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 9304420

Targeting the treatment of drug abuse with molecular imaging. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Targeting the treatment of drug abuse with molecular imaging. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Targeting the treatment of drug abuse with molecular imaging.

AFFILIATION: Medical Department, Brookhaven National Laboratory, Upton, NY 11973, USA. wynne@bnl.gov

Country: England

AGENCY: United States NIDA

GRANT: DA16025

ACRONYM: DA

MEDLINETA: Nucl Med Biol

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Targeting the treatment of drug abuse with molecular imaging Related Publications

• Aligning Multiple Whole Genomes with Mercator and MAVID.
• Brain metabolic changes following 4-week citalopram infusion: increased 18FDG uptake and gamma-amino butyric acid levels.
• Claustrophobia during magnetic resonance imaging: cohort study in over 55,000 patients.
• Detecting single quantum dot motion with nanometer resolution for applications in cell biology.
• Early Response of Endothelial Cells to Flow Is Mediated by VE-Cadherin.
• Early umbilical cord clamping contributes to elevated blood lead levels among infants with higher lead exposure.
• Effect of type 1 diabetes on psychosocial maturation in young adults.
• Frequency of referral of patients with safety-related contraindications to magnetic resonance imaging.
• Indicators for feeding practices in children.
• Investigation of exposure to swine influenza viruses in Ontario (Canada) finisher herds in 2004 and 2005.
• Modern syphilotherapy.
• Multislice computed tomography: angiographic emulation versus standard assessment for detection of coronary stenoses.
• Newborn wet and soiled diaper counts and timing of onset of lactation as indicators of breastfeeding inadequacy.
• Optimizing experimental protocols for quantitative behavioral imaging with 18F-FDG in rodents.
• Reticulum cell sarcoma of the malar zygomatic region; report of case.
• Serial microPET measures of the metabolic reaction to a microdialysis probe implant.
• Studies on the biochemistry of Tetrahymena; B vitamin requirements.
• Studies on the biochemistry of Tetrahymena; components of factor II of known chemical nature.
• Studies on the biochemistry of Tetrahymena; pyridoxine, pyridoxal, and pyridoxamine.
• Studies on the biochemistry of Tetrahymena; the activity of natural purines and pyrimidine.
• Synthesis and pharmacological evaluation of phenylethynyl[1,2,4]methyltriazines as analogues of 3-methyl-6-(phenylethynyl)pyridine.
• THE HISTORY OF NEUROLOGY IN CHICAGO.
• TRIANGLE PINNING FOR FRACTURE OF THE FEMORAL NECK. A NEW METHOD BASED UPON THE INTERNAL ARCHITECTURE.
• Targeting the treatment of drug abuse with molecular imaging.
• The biological activity of substituted purines.
• The biological activity of substituted pyrimidines.
• The effects of inhaled acetone on place conditioning in adolescent rats.
• Tryptophan and nicotinamide in the nutrition of the animal microorganism, Tetrahymena.
• Why invest in a national public health program for stroke? An example using Australian data to estimate the potential benefits and cost implications.
• mGluR5 antagonists that block calcium mobilization in vitro also reverse (S)-3,5-DHPG-induced hyperalgesia and morphine antinociceptive tolerance in vivo.